Trial Profile

A phase 2 study to evaluate the novel combination of Carrick's samuraciclib (CT7001) and Menariniis oral selective estrogen receptor degrader (SERD), elacestrant, in patients with CDK4/6i resistant HR+, HER2- metastatic breast cancer

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 22 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Dec 2022 New trial record
19 Dec 2022 According to a Menarini media release, Carrick anticipates initiating this clinical trial in 2023.
19 Dec 2022 According to a Menarini media release, Carrick Therapeutics and The Menarini Group Announce Clinical Trial Collaboration to execute this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com